Pulmonx Q3 2026 Earnings Date & Estimates

Pulmonx (NASDAQ:LUNG) is a medical device company focused on developing and commercializing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its technologies are designed to improve lung function and quality of life by reducing the impact of damaged, overinflated portions of the lungs.

The company’s primary product is the Zephyr Endobronchial Valve, a small, one-way valve placed in the airways during a bronchoscopic procedure. The valve is intended to block airflow into diseased areas of the lung while allowing trapped air and fluids to escape, helping healthier portions of the lung function more effectively. Pulmonx also offers the Chartis Pulmonary Assessment System, which helps physicians evaluate airway anatomy and collateral ventilation to identify patients who may be appropriate candidates for Zephyr Valve treatment.

Pulmonx markets its products through direct sales and distribution channels in the United States and international markets. The Zephyr Valve has received regulatory authorization in the United States and is available in various other geographies, including Europe. The company’s business is centered on expanding awareness and adoption of bronchoscopic lung volume reduction as a less invasive alternative for appropriately selected patients with severe emphysema.